Bristol-Myers Squibb Company stock price

Bristol-Myers Squibb Company latest news:


  • 02/15/2018 08:39:58

    Bristol-Myers's stock surges toward 18-month high after Morgan Stanley turns bullish

    Bristol-Myers Squibb Co.'s stock shot up 4.1% toward an 18-month high in morning trade Thursday, after Morgan Stanley turned bullish on the drugmaker, for the first time in 18 months, citing "compelling" immuno-oncology growth prospects. Analyst David Risinger raised his rating to overweight, after being at equal weight since Aug. 5, 2016, and boosted his stock price target to $78 from $63. Risinger said after he "dug deeper" into the company's release of the phase 3 Checkmate-227 study of Opdivo plus Yervoy combination versus chemotherapy, his investment thesis has changed: "We have greater confidence that Bristol's Opdivo + Yervoy combination regimen can play a meaningful role in first-line lung cancer, which is the largest cancer market." The stock was on track to close at the highest level since Aug. 4, 2016. It has now run up 11.5% over the past three months, while the SPDR Health Care Select Sector ETF has gained 4.3% and the S&P 500 has climbed 5.6%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 02/14/2018 12:06:47

    Valentine's Day deal is true love for Nektar and Bristol-Myers

    The deal limits Bristol-Myers' upfront payments while giving the drugmaker a cut of promising new drug NKTR-214. A new deal between Bristol-Myers Squibb Co. and Nektar Therapeutics (NKTR) came up candy hearts and roses for investors, sending Nektar shares up 12.5% and Bristol-Myers shares up 2.8% in heavy Wednesday trade. The deal is structured in a relatively complex way, effectively serving to limit Bristol-Myers' upfront payments while giving the drugmaker a cut of net profits...

  • 02/05/2018 11:58:20

    Bristol-Myers Squibb claims 'breakthrough' lung-cancer treatment

    Bristol-Myers Squibb is claiming a "breakthrough" in lung-cancer research with a potential alternative treatment to chemotherapy.        

  • 02/05/2018 10:02:24

    Bristol-Myers touts lung cancer breakthrough, but critics cry foul

    Bristol-Myers shares drop 2.3% after company's overhaul of its clinical trial design is criticized. Bristol-Myers Squibb Co. (BMY) showed off positive results for a late-stage clinical trial early Monday, which the company said showed its drug combination worked but also advanced the scientific understanding of how to treat lung cancer-- and potentially other types of cancer, too. The results are "a breakthrough in cancer research," as well as for advanced lung cancer patients, Chief...

  • 02/05/2018 10:02:24

    Bristol-Myers surges 5.6% on advanced lung cancer trial results, Q4 earnings

    Bristol-Myers Squibb Co.(BMY) shares surged 5.6% in premarket trade on Monday after the company reported positive results for its Opdivo and Yervoy cancer drug combination in a late-stage clinical trial, along with fourth-quarter profit and revenue beats. In the phase 3 trial, the two-drug combination improved progression-free survival in patients with advanced lung cancer as compared with chemotherapy. The trial will continue because an interim analysis looking at overall...

  • 01/25/2018 14:19:43

    BRIEF-Five Prime Therapeutics Announces $25 Mln Payment By Bristol-Myers Squibb

    * FIVE PRIME THERAPEUTICS ANNOUNCES $25 MILLION PAYMENT BY BRISTOL-MYERS SQUIBB FOR CABIRALIZUMAB DEVELOPMENT MILESTONE

  • 01/16/2018 11:32:29

    Merck leaps past rivals with latest lung cancer drug results

    Shares of rivals Bristol-Myers Squibb and Roche drop on the news. Merck& Co. Inc. shares surged 7% in extremely heavy trade Tuesday after the company announced that its key cancer drug Keytruda had positive results in a late-stage clinical trial for advanced lung cancer. Keytruda has already been approved for this indication, last year.

  • 01/05/2018 16:04:40

    Bristol-Myers sees $3 billion tax hit in fourth quarter 2017

    Bristol-Myers Squibb Co(BMY) will record a $3 billion charge in the fourth quarter of 2017 as a result of the U.S. tax reform law passed last month, the drugmaker said in a regulatory filing on Friday. The expense is primarily related to taxes on unremitted offshore earnings, the company said.

  • 12/13/2017 16:34:22

    BRIEF-Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting ...

    Bristol-Myers Squibb Co(BMY): * BRISTOL-MYERS SQUIBB GRANTED EXCLUSIVE LICENSE BY ONO PHARMACEUTICAL FOR MULTIPLE PROGRAMS TARGETING IMMUNO-SUPPRESSIVE FACTORS IN THE TUMOR MICROENVIRONMENT. * Bristol-Myers Squibb Co(BMY) - BRISTOL-MYERS SQUIBB WILL MAKE AN UPFRONT PAYMENT OF $40 MILLION TO ONO.

  • 12/13/2017 16:34:07

    BRIEF-Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting Immuno-Suppressive Factors In The Tumor Microenvironment

    * BRISTOL-MYERS SQUIBB GRANTED EXCLUSIVE LICENSE BY ONO PHARMACEUTICAL FOR MULTIPLE PROGRAMS TARGETING IMMUNO-SUPPRESSIVE FACTORS IN THE TUMOR MICROENVIRONMENT

  • 12/13/2017 15:44:48

    BRIEF-U.S. FDA Accepts Bristol-Myers Squibb’S Application For Opdivo (Nivolumab) Plus Yervoy (Ipilimumab)

    Bristol-Myers Squibb Co(BMY): * U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS BRISTOL-MYERS SQUIBB’S APPLICATION FOR OPDIVO PLUS YERVOY IN INTERMEDIATE- AND POOR-RISK PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AND GRANTS PRIORITY REVIEW. * Bristol-Myers Squibb Co (BMY) - APPLICATION HAS AN ACTION DATE OF APRIL 16, 2018.

  • More trends:

    Bristow Group IncBRS | Brixmor Property Group Inc.BRX | Broadridge Financial SolutionsBR | Brookdale Senior Living Inc.BKD | Brookfield Asset Management IncBAM | Brookfield Canada Office PropertiesBOXC | Brookfield DTLA Inc.DTLA^ | Brookfield Global Listed Infrastructure Income FunINF | Brookfield High Income Fund Inc.HHY | Brookfield Infrastructure Partners LPBIP |